NYSE:NVRONevro Stock Price, Forecast & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVRO stock has increased by 28.4% and is now trading at $141.06.
View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nevro.

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Nevro.

Nevro Corp (NYSE:NVRO) posted its quarterly earnings data on Wednesday, August, 5th. The medical equipment provider reported ($1.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.44. Nevro had a negative return on equity of 46.48% and a negative net margin of 27.22%.
View Nevro's earnings history.

12 equities research analysts have issued 1 year price targets for Nevro's stock. Their forecasts range from $65.00 to $165.00. On average, they expect Nevro's stock price to reach $128.58 in the next twelve months. This suggests that the stock has a possible downside of 8.8%.
View analysts' price targets for Nevro.

News stories about NVRO stock have been trending very positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nevro earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Nevro.

Some companies that are related to Nevro include Teleflex (TFX), ABIOMED (ABMD), Insulet (PODD), Penumbra (PEN), Novocure (NVCR), Tandem Diabetes Care (TNDM), Hill-Rom (HRC), Globus Medical (GMED), Irhythm Technologies (IRTC), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Inari Medical (NARI) and Inspire Medical Systems (INSP).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Adobe (ADBE), AbbVie (ABBV), Trade Desk (TTD), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP) and Vertex Pharmaceuticals (VRTX).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (1.19%), Jennison Associates LLC (0.47%), Principal Financial Group Inc. (0.47%), Granite Investment Partners LLC (0.25%), Swiss National Bank (0.20%) and New York State Common Retirement Fund (0.13%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Mackay Shields LLC, SG Americas Securities LLC, Trexquant Investment LP, Mutual of America Capital Management LLC, State Board of Administration of Florida Retirement System, Arizona State Retirement System, and Comerica Bank. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, and Shawn Mccormick.
View insider buying and selling activity for Nevro.

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Granite Investment Partners LLC, Principal Financial Group Inc., Quantitative Systematic Strategies LLC, Foundry Partners LLC, Polianta Ltd, Swiss National Bank, and New York State Common Retirement Fund. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $141.06.

Nevro has a market capitalization of $4.84 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]